Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04479241 · ClinicalTrials.gov registry record · Phase 2
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
A Phase 2 study of Glioblastoma and Brain Tumor, sponsored by Istari Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 10
- Study locations
NCT04479241 is a Phase 2 study of Glioblastoma and Brain Tumor that has completed, run by Istari Oncology. The registered enrollment target is 25 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (77% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT04479241, a Phase 2 study of Glioblastoma and Brain Tumor, has completed, sponsored by Istari Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 10
- Study locations
Study Summary
This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.
Conditions Studied
Interventions
- BIOLOGICAL pembrolizumab
- BIOLOGICAL lerapolturev
Study Locations (10)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University - Columbus
California
- University of California San Francisco - San Francisco
Connecticut
- UConn Health - Farmington
Florida
- Baptist MD Anderson Cancer Center - Jacksonville
North Carolina
- Duke University Medical Center - Durham
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-10-21 |
| Est. Completion | 2024-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04479241
The ClinicalTrials.gov registry entry for NCT04479241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (77% lower). The listed sponsor is Istari Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT04479241 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT04479241 about?
NCT04479241 is a clinical study titled "LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma". This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety, tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.
What is the current status of trial NCT04479241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-10-21. Estimated completion is 2024-06-21.
What conditions does trial NCT04479241 study?
This clinical trial studies the following conditions: Glioblastoma, Brain Tumor, Recurrent Glioblastoma, Supratentorial Glioblastoma.
What interventions are being tested in trial NCT04479241?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), lerapolturev (BIOLOGICAL).
Who is sponsoring clinical trial NCT04479241?
This trial is sponsored by Istari Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04479241 being conducted?
This trial has 10 study locations across California, Connecticut, Florida, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.